Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Clin Exp Immunol ; 184(3): 332-7, 2016 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-26749258

RESUMO

Selective immunoglobulin A (IgA) deficiency (IgAD) is the most common primary immunodeficiency in the western world. The aim of the study was to investigate the prevalence and clinical characteristics of Helicobacter pylori-infected dyspeptic patients with IgAD. Case samples were drawn from all subjects ≥ 12 years of age (n = 104729) who had undergone serum total IgA measurements during 2004-14 for any reason at Leumit Healthcare Services (Israel) and had serum total IgA < 0·07 g/l. The control group was comprised of a random sample of remaining patients with a case-control ratio of 10 controls for each case. The dyspeptic diseases were identified and retrieved from Leumit Health Care Services electronic database using specific ICD-9-CM diagnostic codes. The case group included 347 subjects and the control group 3470 subjects. There were no significant differences in the prevalence of patients with dyspepsia [84 (24·2%) versus 821 (23·6%) for cases and controls, respectively]. Additionally, there was no difference in a proportion of dyspeptic H. pylori-positive subjects [59 (17·1%) versus 524 (15·1%)] between the case and control groups. Only 59 (17%) among the 347 IgAD patients underwent gastroscopy. A significantly larger proportion of case subjects experienced several forms of gastritis [13 (61·9%) versus 38 (21·6%), P < 0·001), duodenal ulcers [seven (33·3%) versus 19 (10·8%); P = 0·01] and nodular lymphoid hyperplasia (NLH) [two (9·5%) versus none; P = 0·011]. IgAD is not associated with increased prevalence of H. pylori-associated dyspepsia; nevertheless, H. pylori-infected dyspeptic IgAD subjects experience more EGD-proved gastritis, duodenal ulcers and NLH.


Assuntos
Hiperplasia do Linfonodo Gigante/diagnóstico , Úlcera Duodenal/diagnóstico , Dispepsia/diagnóstico , Gastrite/diagnóstico , Infecções por Helicobacter/diagnóstico , Deficiência de IgA/diagnóstico , Adolescente , Adulto , Idoso , Estudos de Casos e Controles , Hiperplasia do Linfonodo Gigante/complicações , Hiperplasia do Linfonodo Gigante/imunologia , Criança , Bases de Dados Factuais , Úlcera Duodenal/complicações , Úlcera Duodenal/imunologia , Dispepsia/imunologia , Registros Eletrônicos de Saúde , Gastrite/complicações , Gastrite/imunologia , Infecções por Helicobacter/complicações , Infecções por Helicobacter/imunologia , Helicobacter pylori/crescimento & desenvolvimento , Helicobacter pylori/imunologia , Humanos , Deficiência de IgA/complicações , Deficiência de IgA/imunologia , Imunoglobulina A/sangue , Israel , Pessoa de Meia-Idade
2.
Arch Dermatol Res ; 306(1): 67-74, 2014 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-23591742

RESUMO

Rituximab has recently been reported in retrospective studies to be effective in pemphigus at the dosing schedule used for treating rheumatoid arthritis (RA) of two 1,000 mg infusions 2 weeks apart. While the effect of rituximab on B cells has been well described, its effect on global T cell function has not been assessed. Ten patients who received RA dosage rituximab were prospectively assessed for clinical response. Immunological response including autoantibody titers, CD20+ B cell, and CD4+ T cell counts was assessed pre- and post-treatment. The CD4+ T cell function was determined by a novel assay measuring intracellular ATP levels in response to mitogenic stimulus. At 6 months, 90 % of patients achieved remission. Disease control and remission were achieved at median times of 1 and 3.7 months, respectively. There was a 67 % relapse rate during an average follow-up of 22 months. Global CD4+ T cell numbers and function were preserved 3 months after rituximab. A single cycle of RA dosage rituximab with concomitant immunosuppression is effective in pemphigus. We did not find an effect on total CD4+ T cell numbers or function 3 months after treatment.


Assuntos
Anticorpos Monoclonais Murinos/uso terapêutico , Autoanticorpos/sangue , Linfócitos B/imunologia , Linfócitos T CD4-Positivos/imunologia , Pênfigo/tratamento farmacológico , Adulto , Idoso , Antígenos CD20/sangue , Antineoplásicos/uso terapêutico , Contagem de Linfócito CD4 , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Recidiva , Rituximab , Resultado do Tratamento
3.
Vaccine ; 25(6): 1071-5, 2007 Jan 22.
Artigo em Inglês | MEDLINE | ID: mdl-17052814

RESUMO

A retrospective study was conducted to verify the possibility that people immunized with pneumococcal vaccine (PV) show lower morbidity not only for pneumonia but also for influenza. A total of 450 individuals were enrolled between 1999 and 2003 and allocated to one of the following groups: (A) not vaccinated; (B) immunized with PV during 1999; (C) immunized with anti-influenza vaccine (Flu-V) each year; and (D) immunized with PV once in 1999 and Flu-V every consecutive year. People from group B showed significantly lower percentage of influenza-related diseases during the year 2000 in comparison with those from group A (p<0.01), whereas in the course of 2001 the morbidity of patients from group B was lower compared with the other groups (p<0.01). The results point to a way to decrease the morbidity of influenza-related diseases by immunization with PV only, at least for 2-3 years, avoiding Flu-V administration and permitting considerable saving for health care providers. Therefore, it is concluded that PV can reduce the morbidity of influenza at a greater rate than the Flu-V.


Assuntos
Influenza Humana/epidemiologia , Influenza Humana/terapia , Vacinas Pneumocócicas/administração & dosagem , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Vacinas contra Influenza/administração & dosagem , Vacinas contra Influenza/economia , Vacinas contra Influenza/imunologia , Influenza Humana/imunologia , Masculino , Pessoa de Meia-Idade , Morbidade , Vacinas Pneumocócicas/economia , Vacinas Pneumocócicas/imunologia , Estudos Retrospectivos
4.
J Clin Pharm Ther ; 29(5): 437-41, 2004 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-15482387

RESUMO

CONTEXT: Trimethoprim-sulfamethoxazole (TMP-SMX) and nitrofurantoin were until recently the two drugs recommended in clinical guidelines in Israel for empiric treatment of uncomplicated urinary tract infection (UTI) in women. OBJECTIVES: The objective of this study is to evaluate the economic impact of physician non-adherence to these recommendations. DESIGN SETTING AND PATIENTS: Data were derived from the electronic patient records of the Leumit Health Fund. Cases of women aged 18 to 75 with a diagnosis of acute cystitis or UTI that were empirically treated with antibiotics from January 2001 to June 2002 were identified. The final sample comprised 7738 physician-patient encounters. The proportion of cases treated with each individual drug was calculated, and the excess expenditure because of non-adherence to guidelines from the perspective of the Health Maintenance Organization (HMO) was evaluated using 5 days of therapy with nitrofurantoin as the reference treatment. RESULTS: TMP-SMX was the most frequently prescribed drug (25.81%), followed by nitrofurantoin (14.71%) representing a 40.52% rate of adherence to the guidelines. Drugs from the fluoroquinolone family were prescribed in 22.82% of cases. Cost of treatment in approximately 70% of the cases exceeded the expected cost of the guideline therapy. CONCLUSIONS: Suboptimal adherence to the guidelines resulted in a significant and avoidable waste of the health plan's resources in both drugs and money.


Assuntos
Anti-Infecciosos Urinários/economia , Anti-Infecciosos Urinários/uso terapêutico , Fidelidade a Diretrizes , Nitrofurantoína/economia , Nitrofurantoína/uso terapêutico , Padrões de Prática Médica/estatística & dados numéricos , Combinação Trimetoprima e Sulfametoxazol/economia , Combinação Trimetoprima e Sulfametoxazol/uso terapêutico , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/economia , Adolescente , Adulto , Idoso , Análise Custo-Benefício , Custos e Análise de Custo , Feminino , Custos de Cuidados de Saúde/estatística & dados numéricos , Sistemas Pré-Pagos de Saúde/estatística & dados numéricos , Humanos , Sistemas Computadorizados de Registros Médicos/estatística & dados numéricos , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Padrões de Prática Médica/economia , Estudos Retrospectivos
5.
Am J Clin Pathol ; 97(5): 663-4, 1992 May.
Artigo em Inglês | MEDLINE | ID: mdl-1575211

RESUMO

Cerebrospinal fluid from a 42-year-old man with acquired immune deficiency syndrome was processed in a Coulter S-plus counter and found to contain "4.8 x 10(9) leukocytes/L:56.1% granulocytes and 37.7% lymphocytes." Direct examination of the same specimen in a counting chamber revealed that the leukocytes were cells of Cryptococcus neoformans. Coulter analysis of cerebrospinal fluid may be inappropriate, particularly when yeast infection is a probable diagnosis.


Assuntos
Contagem de Células Sanguíneas/instrumentação , Cryptococcus/isolamento & purificação , Leucócitos/patologia , Meningite Criptocócica/microbiologia , Síndrome da Imunodeficiência Adquirida/líquido cefalorraquidiano , Adulto , Líquido Cefalorraquidiano/citologia , Líquido Cefalorraquidiano/microbiologia , Erros de Diagnóstico , Humanos , Masculino , Meningite Criptocócica/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...